Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 873-883

  Lindesmith, Lisa C ^a   Debbink, Kari ^b   Swanstrom, Jesica ^a   Vinjé, Jan ^c   Costantini, Verónica ^c   Baric, Ralph S ^a,b   Donaldson, Eric F ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; MONOCLONAL ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GENOTYPE; HERD IMMUNITY; LIGAND BINDING; MOLECULAR EVOLUTION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; VIRUS LIKE AGENT; VIRUS MUTANT; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; BIOLOGICAL EVOLUTION; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; EPITOPE MAPPING; GASTROENTERITIS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; NOROVIRUS;

MUS; NOROVIRUS;

EID: 84856943397     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06200-11     Document Type: Article

References (50)

1. Allen DJ, Gray JJ, Gallimore CI, Xerry J, Iturriza-Gomara M. 2008. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 3:e1485.
2. Anonymous. 2007. Norovirus activity-United States, 2006-2007. MMWR Morb. Mortal. Wkly. Rep. 56:842-846.
3. Anonymous. 2011. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recommend. Rep. 60(RR-3):1-18.
4. Baric RS, et al. 2002. Expression and self-assembly of Norwalk virus capsid protein from Venezuelan equine encephalitis virus replicons. J. Virol. 76:3023-3030.
5. Bok K, et al. 2009. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J. Virol. 83:11890-11901.
6. Bok K, et al. 2011. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108: 325-330.
7. Bull RA, Eden JS, Rawlinson WD, White PA. 2010. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog. 6:e1000831.
8. Bull RA, Tu ET, McIver CJ, Rawlinson WD, White PA. 2006. Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis. J. Clin. Microbiol. 44:327-333.
9. Cannon JL, et al. 2009. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J. Virol. 83:5363-5374.
10. Cao S, et al. 2007. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 81:5949-5957.
11. Cheetham S, et al. 2006. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80:10372-10381.
12. Chen R, Neill JD, Estes MK, Prasad BV. 2006. X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc. Natl. Acad. Sci. U. S. A. 103:8048-8053.
13. Chen, Y., et al. 2011. Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog. 7(7):e1002152.
14. Chenna R, et al. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31:3497-3500.
15. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. 2012. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J. Virol. 86:1214-1226.
16. de Rougemont A, et al. 2011. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J. Virol. 85:4057-4070.
17. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225:190-211.
18. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2010. Viral shapeshifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8:231-241.
19. Estes MK, Prasad BV, Atmar RL. 2006. Noroviruses everywhere: has something changed? Curr. Opin. Infect. Dis. 19:467-474.
20. Fankhauser RL, et al. 2002. Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States. J. Infect. Dis. 186:1-7.
21. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. 2002. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76:12335-12343.
22. Harris JP, Edmunds WJ, Pebody R, Brown DW, Lopman BA. 2008. Deaths from norovirus among the elderly, England and Wales. Emerg. Infect. Dis. 14:1546-1552.
23. Hutson AM, Atmar RL, Estes MK. 2004. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol. 12: 279-287.
24. Jiang X, Wang M, Graham D, Estes M. 1992. Expression, self-assembly and antigenicity of the Norwalk virus capsid protein. J. Virol. 66: 6527-6532.
25. Koopmans M, et al. 2000. Molecular epidemiology of human enteric caliciviruses in The Netherlands. J. Infect. Dis. 181(Suppl. 2):S262-S269.
26. Kroneman A, et al. 2006. Increase in norovirus activity reported in Europe. Euro Surveill. 11:E061214.1.
27. Lindesmith L, et al. 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9:548-553.
28. Lindesmith LC, et al. 2010. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84:1800-1815.
29. Lindesmith LC, Donaldson EF, Baric RS. 2011. Norovirus GII.4 strain antigenic variation. J. Virol. 85:231-242.
30. Lindesmith LC, et al. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5:e31.
31. LoBue AD, et al. 2006. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24:5220-5234.
32. Lochridge VP, Hardy ME. 2007. A single-amino-acid substitution in the P2 domain of VP1 of murine norovirus is sufficient for escape from antibody neutralization. J. Virol. 81:12316-12322.
33. Lochridge VP, Jutila KL, Graff JW, Hardy ME. 2005. Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J. Gen. Virol. 86:2799-2806.
34. Marionneau S, Airaud F, Bovin NV, Le Pendu J, Ruvoen-Clouet N. 2005. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. J. Infect. Dis. 192: 1071-1077.
35. Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. 1999. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J. Infect. Dis. 179:1334-1344.
36. Okada M, Tanaka T, Oseto M, Takeda N, Shinozaki K. 2006. Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch. Virol. 151:1635-1641.
37. Patel MM, et al. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-1231.
38. Phan TG, et al. 2006. Changing distribution of norovirus genotypes and genetic analysis of recombinant GIIb among infants and children with diarrhea in Japan. J. Med. Virol. 78:971-978.
39. Prasad BV, et al. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290.
40. Reeck A, et al. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J. Infect. Dis. 202:1212-1218.
41. Schorn R, et al. 2010. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin. Infect. Dis. 51:307-314.
42. Shanker S, et al. 2011. Structural analysis of HBGA binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J. Virol. 85:8635-8645.
43. Siebenga J, Kroneman A, Vennema H, Duizer E, Koopmans M. 2008. Food-borne viruses in Europe network report: the norovirus GII.4 2006b (for US named Minerva-like, for Japan Kobe034-like, for UK V6) variant now dominant in early seasonal surveillance. Euro Surveill. 13(2):8009.
44. Siebenga JJ, et al. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81:9932-9941.
45. Tian P, et al. 2007. Binding of recombinant norovirus like particle to histo-blood group antigen on cells in the lumen of pig duodenum. Res. Vet. Sci. 83(3):410-418.
46. Tian P, et al. 2010. Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J. Appl. Microbiol. 109:1753-1762.
47. Vinjé J, Altena S, Koopmans M. 1997. The incidence and genetic variability of small round-structured viruses in outbreaks of gastroenteritis in The Netherlands. J. Infect. Dis. 176:1374-1378.
48. Widdowson MA, et al. 2004. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus-United States, 2002. J. Infect. Dis. 190:27-36.
49. Yang Y, et al. 2010. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J. Virol. 84:9595-9607.
50. Zheng DP, et al. 2006. Norovirus classification and proposed strain nomenclature. Virology 346:312-323.